What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Test Name
Test Title, Test Company

Read biography×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Amy Miller
Executive Vice President, PMC

Read biography×

Amy Miller
Executive Vice President, PMC

Follow Amy on:

For nearly a decade, Amy Miller, Ph.D., Executive Vice President for the Personalized Medicine Coalition (PMC), has worked with innovators, scientists, providers, and payers to reach consensus on policy issues impacting personalized medicine.  Before joining the PMC, Miller worked in the office of the Director of the National Institute of Mental Health where she served as a liaison among the scientific community, the legislative branch, and the consumers of mental health care and their families.  A former AAAS fellow, she also served as a domestic policy advisor to Senator Jay Rockefeller.  She began her career as a researcher at National Institute of Child Health and Human Development.  Miller received a BA from the University of New Orleans and holds a doctoral degree in Human Development from the University of Connecticut.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Raju Kucherlapati
Professor, Department of Genetics, Harvard Medical School

Read biography×

Raju Kucherlapati
Professor, Department of Genetics, Harvard Medical School

Follow Raju on:

Raju Kucherlapati, Ph.D., is the Paul C. Cabot Professor in the Harvard Medical School Department of Genetics. He is also a professor in the Department of Medicine at Brigham and Women’s Hospital.

Dr. Kucherlapati was the first Scientific Director of the Harvard Medical School-Partners Healthcare Center for Genetics and Genomics. His research focuses on gene mapping, gene modification, and cloning disease genes. From 1989-2001, Dr. Kucherlapati was the Lola and Saul Kramer Professor of Molecular Genetics and Chairman of the Department at the Yeshiva University Albert Einstein College of Medicine. He was previously a professor in the Department of Genetics at the University of Illinois, College of Medicine. He began his research as an assistant professor in the Department of Biochemical Sciences at Princeton University.

He has chaired numerous NIH committees and served on the National Advisory Council for Human Genome Research and the NCI Mouse Models for Human Cancer Consortium. He is also a member of the Cancer Genome Atlas project of the National Institutes of Health. He is a member of the Institute of Medicine of the National Academy of Sciences and a fellow of the American Association for the Advancement of Science.

Dr. Kucherlapati received his B.S. and M.A. in Biology from universities in India, and he received his Ph.D. from the University of Illinois at Urbana, as well as conducting post-doctoral work at Yale University.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Donna R. Cryer, JD
CEO, Global Liver Institute

Read biography×

Donna R. Cryer, JD
CEO, Global Liver Institute

Donna Cryer is the President and CEO of the American Liver Foundation, the largest and oldest national non-profit organization serving liver disease patients and their families. Prior to this experience, she served as the chief executive officer of CryerHealth, an international healthcare consulting firm focused on patient engagement and alliance development.

Ms. Cryer’s almost two decades of diverse experiences have provided her with a 360 degree perspective on health care, spanning associations, hospital consulting, PR and clinical trial recruitment firms. Her journey as a patient advocate began with her own liver transplant and a desire to improve the health care system for other patients, first manifesting in a position as patient affairs specialist for the United Network for Organ Sharing. Ms. Cryer subsequently worked with hospital C-suite and cancer center directors at the Advisory Board Company and Association for Community Cancer Centers. She helped rebuild the health care practice at public relations powerhouse Hill & Knowlton’s Washington, DC office and the multicultural practice of clinical trial recruitment firm Matthews Media Group (now part of Ketchum). Ms. Cryer has created successful patient education, outreach, and recruitment campaigns and coalitions in oncology, cardiology, neurology, and renal health.

A graduate of Harvard/Radcliffe Colleges and Georgetown University Law Center, Ms. Cryer is a member of the Virginia State Bar. She sits on many advisory boards and is currently serving a five-year term as a patient representative to the U.S. Food and Drug Administration.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Randy Burkholder
VP, Policy, PhRMA

Read biography×

Randy Burkholder
VP, Policy, PhRMA

Follow Randy on:

Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including issues involving comparative effectiveness research, health technology assessment, payment and delivery reform (accountable care organizations and bundled payment policy), appropriate use and patient adherence, and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, CMS’ Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research.  He also is a former member of the Board of Directors of the Personalized Medicine Coalition and serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.

Mr. Burkholder has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.

×

What key benefits of personalized medicine do you think the public needs to know about in order to embrace this approach to health care?

Mark Richards
Senior Vice President, Management Supervisor, KRC Research

Read biography×

Mark Richards
Senior Vice President, Management Supervisor, KRC Research

Follow Mark on:

Mark Richards is a Senior Vice President at KRC Research. He is a leader in KRC’s healthcare, risk and crisis communications, energy, and legal services practices.

Mark is a sociologist who specializes in public opinion and communications research. For the past two decades he has led quantitative and qualitative research projects to identify insights and advise public and private clients. Mark is also an expert on risk and crisis communication, issues management, and controversial facility siting.

Before joining KRC Research, Mark was Senior Research Associate with Bisconti Research, Inc. He is a member of the American Association for Public Opinion Research (AAPOR).

Mark received his Ph.D. in Sociology and Public Policy from The Union Institute in 2001.

×

04/15/14: How can we assure that the 340B program provides access to discounted medicines to the indigent and vulnerable patients the program was designed to serve?

Back to Top

Contributors:

              
Eric Hargis , CEO, Colon Cancer Alliance
Texas BioAlliance, Partner, 340B Contributor
Kyle Keeney, Ph.D., KLSC
Michael Hazel, President, Texas Nurse Practitioners
CTD, Partner, 340B Contributor
SWHR, Society for Women’s Health Research, 340B Contributor
The North Carolina State Grange, Contributor, The North Carolina State Grange

Join The Conversation

04/09/14: See What Industry Leaders, Legislators, Experts and PhRMA Members are Discussing Now at PhRMA’s Annual Meeting. Join the Conversation Using #PhRMA14

Back to Top

Contributors:

                          
Amy Comstock Rick, CEO, Parkinson’s Action Network
Sally Greenberg, Executive Director, National Consumers League
Sharon F. Terry , President and CEO , Genetic Alliance
Wendy K.D. Selig , President and CEO, Melanoma Research Alliance
Millicent Gorham, #PhRMA14 Attendee, Nat. Black Nurses Assoc.
Andrew Sperling, #PhRMA14 Attendee, NAMI
Carl Schmid, Deputy Executive Director, The AIDS Institute
Scott Smith, #PhRMA14 Attendee, GlaxoSmithKline
Christopher W. Hansen, President, ACS CAN
Randall L. Rutta, Chief Strategy Officer, Executive Vice President, Easter Seals
Danielle Pere, #PhRMA14 Attendee, ACPM
David Miller, President and CEO , iBIO
Jeffrey M. Gallagher, CEO, Virginia Bio

Join The Conversation

03/26/14: What is the greatest issue facing Parkinson’s patients today, and what can be done to accelerate the research and development of new therapies to help them?

Back to Top

Contributors:

                  
Amy Comstock Rick, CEO, Parkinson’s Action Network
Todd Sherer, CEO, Michael J. Fox Foundation
Gabriela Lavezzari, AVP, Scientific Affairs , PhRMA
Tom Isaacs, Co-Founder, Cure Parkinson's Trust
Terri Reinhart, Parkinsons Patient, Artist & Writer
EPDA, Contributor, Non-Profit
NINDS, Initiative, NIH
Peter Schmidt, CIO, VP, NPF
Robin Elliott, President, Parkinson’s Disease Foundation

Join The Conversation

Pages